Table 1. Anti-RARα antibodies, ANAs, and... | American Society of Hematology

Table 1.

Anti-RARα antibodies, ANAs, and ANCAs in patients with APL

		Anti-RARα antibody			ANA
Patient no.	Months after treatment†	Diagnosis^*	After treatment†	Diagnosis^*	After treatment†	Diagnosis^*	After treatment†
1	6	+	+	-	++	-	-
2	6	+++	+++	++	++	-	-
3	36	++	++++	-	+	-	-
4	4.7	++++	+++	++	+	-	-
5	67	++++	++++	++	++	-	-
6	6	++	++++	-	-	+	++
7	4	+	+++	+	++	-	-
8	31	+	+++	-	+	++	+
9	10	+	+++	++	++	+	+

		Anti-RARα antibody			ANA
Patient no.	Months after treatment†	Diagnosis^*	After treatment†	Diagnosis^*	After treatment†	Diagnosis^*	After treatment†
1	6	+	+	-	++	-	-
2	6	+++	+++	++	++	-	-
3	36	++	++++	-	+	-	-
4	4.7	++++	+++	++	+	-	-
5	67	++++	++++	++	++	-	-
6	6	++	++++	-	-	+	++
7	4	+	+++	+	++	-	-
8	31	+	+++	-	+	++	+
9	10	+	+++	++	++	+	+

Results of anti-RARα antibodies are expressed as semiquantitative values according to specific absorbance (SA) value: SA less than 0.2 (+), SA 0.21 to 0.4 (++), SA 0.41 to 0.6 (+++), SA more than 0.61 (++++). Results of ANAs and ANCAs are expressed as negative (-) if no fluorescence was observed and as weakly positive (+) or strongly positive (++) according to the intensity of the signal. Both ANA and ANCA tests were performed according to standard routine procedures of the Laboratoire d'Immunologie by 2 independent investigators. Briefly, ANAs were detected in the same sera (diluted 1:80) by indirect immunofluorescence with commercial Hep2000 cells (Immunoconcepts; BMD, Marne la Vallée, France).⁹ ANCAs were tested in sera (diluted 1:20) by indirect immunofluorescence with commercial human neutrophils (Inova Diagnostics, San Diego, CA).¹⁰

Day 0 of therapy for all patients.

†

After maintenance therapy (delay in months is given for each patient).

View Large

This Feature Is Available To Subscribers Only